Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1][3] Lonapegsomatropin is a prodrug of somatropin.[1]
Lonapegsomatropin was approved for medical use in the United States in August 2021,[1][2][5] and in the European Union in January 2022.[3]
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]
The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.[6]
Antagonists: Pegvisomant
This hormonal preparation article is a stub. You can help Wikipedia by expanding it.